336 related articles for article (PubMed ID: 22700955)
21. Sulfonate-modified phenylboronic acid-rich nanoparticles as a novel mucoadhesive drug delivery system for vaginal administration of protein therapeutics: improved stability, mucin-dependent release and effective intravaginal placement.
Li C; Huang Z; Liu Z; Ci L; Liu Z; Liu Y; Yan X; Lu W
Int J Nanomedicine; 2016; 11():5917-5930. PubMed ID: 27877038
[TBL] [Abstract][Full Text] [Related]
22. Acyclovir treatment of experimental genital herpes simplex virus infections.
Kern ER
Am J Med; 1982 Jul; 73(1A):100-8. PubMed ID: 6285699
[TBL] [Abstract][Full Text] [Related]
23. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo.
Xu Q; Ensign LM; Boylan NJ; Schön A; Gong X; Yang JC; Lamb NW; Cai S; Yu T; Freire E; Hanes J
ACS Nano; 2015 Sep; 9(9):9217-27. PubMed ID: 26301576
[TBL] [Abstract][Full Text] [Related]
24. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2.
Parr EL; Parr MB
Immunology; 1999 Dec; 98(4):639-45. PubMed ID: 10594699
[TBL] [Abstract][Full Text] [Related]
25. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.
Lai SK; Wang YY; Hanes J
Adv Drug Deliv Rev; 2009 Feb; 61(2):158-71. PubMed ID: 19133304
[TBL] [Abstract][Full Text] [Related]
26. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses.
Lai SK; Wang YY; Hida K; Cone R; Hanes J
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):598-603. PubMed ID: 20018745
[TBL] [Abstract][Full Text] [Related]
27. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?
das Neves J; Amiji M; Sarmento B
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(4):389-99. PubMed ID: 21506290
[TBL] [Abstract][Full Text] [Related]
28. In vitro and ex vivo models for evaluating vaginal drug delivery systems.
Shapiro RL; DeLong K; Zulfiqar F; Carter D; Better M; Ensign LM
Adv Drug Deliv Rev; 2022 Dec; 191():114543. PubMed ID: 36208729
[TBL] [Abstract][Full Text] [Related]
29. Infection: new vaginal drug delivery methods.
Payton S
Nat Rev Urol; 2012 Aug; 9(8):411. PubMed ID: 22750952
[No Abstract] [Full Text] [Related]
30. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
Whaley KJ; Hanes J; Shattock R; Cone RA; Friend DR
Antiviral Res; 2010 Dec; 88 Suppl 1():S55-66. PubMed ID: 21109069
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation.
Schneider CS; Xu Q; Boylan NJ; Chisholm J; Tang BC; Schuster BS; Henning A; Ensign LM; Lee E; Adstamongkonkul P; Simons BW; Wang SS; Gong X; Yu T; Boyle MP; Suk JS; Hanes J
Sci Adv; 2017 Apr; 3(4):e1601556. PubMed ID: 28435870
[TBL] [Abstract][Full Text] [Related]
32. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy.
Mastorakos P; da Silva AL; Chisholm J; Song E; Choi WK; Boyle MP; Morales MM; Hanes J; Suk JS
Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8720-5. PubMed ID: 26124127
[TBL] [Abstract][Full Text] [Related]
33. In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa.
Linehan MM; Richman S; Krummenacher C; Eisenberg RJ; Cohen GH; Iwasaki A
J Virol; 2004 Mar; 78(5):2530-6. PubMed ID: 14963155
[TBL] [Abstract][Full Text] [Related]
34. Vaginal siRNA delivery: overview on novel delivery approaches.
Baxi K; Sawarkar S; Momin M; Patel V; Fernandes T
Drug Deliv Transl Res; 2020 Aug; 10(4):962-974. PubMed ID: 32170657
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model.
Delagrave S; Hernandez H; Zhou C; Hamberger JF; Mundle ST; Catalan J; Baloglu S; Anderson SF; DiNapoli JM; Londoño-Hayes P; Parrington M; Almond J; Kleanthous H
PLoS One; 2012; 7(10):e46714. PubMed ID: 23071620
[TBL] [Abstract][Full Text] [Related]
36. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery.
Cu Y; Booth CJ; Saltzman WM
J Control Release; 2011 Dec; 156(2):258-64. PubMed ID: 21763739
[TBL] [Abstract][Full Text] [Related]
37. Mucosal delivery of herpes simplex virus vaccine.
Bowen JC; Alpar HO; Phillpotts R; Brown MR
Res Virol; 1992; 143(4):269-78. PubMed ID: 1329168
[TBL] [Abstract][Full Text] [Related]
38. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
Destache CJ; Mandal S; Yuan Z; Kang G; Date AA; Lu W; Shibata A; Pham R; Bruck P; Rezich M; Zhou Y; Vivekanandan R; Fletcher CV; Li Q
Antimicrob Agents Chemother; 2016 Jun; 60(6):3633-9. PubMed ID: 27044548
[TBL] [Abstract][Full Text] [Related]
39. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
Parr MB; Kepple L; McDermott MR; Drew MD; Bozzola JJ; Parr EL
Lab Invest; 1994 Mar; 70(3):369-80. PubMed ID: 8145530
[TBL] [Abstract][Full Text] [Related]
40. Topically applied human recombinant monoclonal IgG1 antibody and its Fab and F(ab')2 fragments protect mice from vaginal transmission of HSV-2.
Zeitlin L; Whaley KJ; Sanna PP; Moench TR; Bastidas R; De Logu A; Williamson RA; Burton DR; Cone RA
Virology; 1996 Nov; 225(1):213-5. PubMed ID: 8918548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
